REV-MED recently participated in MEDICA 2022, presenting its cutting-edge cell regeneration therapy systems utilizing autologous stem cells and laser-based devices for pain management.
Held annually since 1969, MEDICA is the world’s largest medical device trade fair, showcasing the latest trends and innovations in the global medical industry. At this year’s event in Germany, REV-MED exhibited its flagship products:
- TriCell PRP Kit
- Hithera 4.0: A laser-based pain management device
- OnyRay: A laser product for treating onychomycosis (nail fungus)
According to REV-MED, OnyRay operates without generating heat, using dual-wavelength laser light to improve and treat nail fungus conditions effectively.
During the exhibition, REV-MED conducted meetings with over 120 companies from 25 countries, including Germany, Italy, Switzerland, Greece, Spain, and Türkiye. These discussions focused on tailoring sales strategies to fit diverse market conditions.
CEO Bongkeun Shin expressed satisfaction with the event, stating, “MEDICA 2022 provided an excellent platform to promote the superior technology and competitiveness of REV-MED’s products. Leveraging the business networks established at this exhibition, we will focus on expanding our presence in international markets.” He added, “By achieving FDA certification and preparing for an IPO, we aim to make 2023 a breakthrough year where REV-MED gains global recognition.”
Founded in 2009, REV-MED specializes in bio-kits that extract and concentrate growth and regenerative factors from sources such as blood, bone marrow, and adipose tissue. The company continues to advance its research and product development for autologous blood concentration systems, contributing to stem cell therapy innovations.
Source: HealthTrends (http://www.k-health.com)
REV-MED recently participated in MEDICA 2022, presenting its cutting-edge cell regeneration therapy systems utilizing autologous stem cells and laser-based devices for pain management.
Held annually since 1969, MEDICA is the world’s largest medical device trade fair, showcasing the latest trends and innovations in the global medical industry. At this year’s event in Germany, REV-MED exhibited its flagship products:
According to REV-MED, OnyRay operates without generating heat, using dual-wavelength laser light to improve and treat nail fungus conditions effectively.
During the exhibition, REV-MED conducted meetings with over 120 companies from 25 countries, including Germany, Italy, Switzerland, Greece, Spain, and Türkiye. These discussions focused on tailoring sales strategies to fit diverse market conditions.
CEO Bongkeun Shin expressed satisfaction with the event, stating, “MEDICA 2022 provided an excellent platform to promote the superior technology and competitiveness of REV-MED’s products. Leveraging the business networks established at this exhibition, we will focus on expanding our presence in international markets.” He added, “By achieving FDA certification and preparing for an IPO, we aim to make 2023 a breakthrough year where REV-MED gains global recognition.”
Founded in 2009, REV-MED specializes in bio-kits that extract and concentrate growth and regenerative factors from sources such as blood, bone marrow, and adipose tissue. The company continues to advance its research and product development for autologous blood concentration systems, contributing to stem cell therapy innovations.
Source: HealthTrends (http://www.k-health.com)